Practical guidePublication & ethicsMedicine & healthcare

CONSORT 2025: what it is, when to use it and how to report a randomised trial

CONSORT is the checklist that tells you what a report of a randomised trial must contain. This guide explains what the statement covers, which trial designs it fits, where it does not apply, and how to use it so a reviewer or examiner can see your trial was conducted and reported properly.

What you will learn

  • Explain what the CONSORT statement is, who maintains it and what it is meant to fix
  • Identify which trial designs CONSORT 2025 covers, and which CONSORT extension applies to your own trial
  • Recognise study designs where CONSORT does not apply, and the guideline you should use instead
  • Use the checklist and flow diagram while writing, not only before submission
  • Read a short worked example contrasting a weak and a CONSORT-compliant results section

What you will unlearn

  • CONSORT is a style guide for formatting a trial paper.It is a minimum reporting checklist about content: what must be stated about design, conduct and analysis, not how the page should look.
  • Any clinical study can be reported with CONSORT.CONSORT 2025 is built for randomised trials; non-randomised and observational studies need STROBE, and trial protocols need SPIRIT.
  • Following the checklist guarantees the trial was well conducted.CONSORT improves the completeness of reporting; it cannot fix a poorly designed or poorly conducted trial, only make its conduct visible.
  • One CONSORT checklist fits every trial design.Cluster, non-inferiority, pragmatic, pilot and other trial types have their own CONSORT extensions with additional or modified items.

Skills you will practise

  • Reading a reporting checklist
  • Choosing the right CONSORT extension
  • Writing a trial flow diagram
  • Describing randomisation and blinding
  • Reporting harms and protocol changes

What CONSORT is and who maintains it

CONSORT, the Consolidated Standards of Reporting Trials, is a checklist and participant flow diagram that sets out the minimum information a report of a randomised controlled trial should contain. It is maintained by an international group of trial methodologists, statisticians, journal editors and patient representatives, and has been revised twice since it was first published in 1996, most recently as CONSORT 2025 (Hopewell et al., 2025).

The current statement has 30 checklist items covering the title and abstract, introduction, methods, results and discussion of a parallel-group randomised trial, together with a flow diagram that tracks participants from screening through enrolment, allocation, follow-up and analysis. CONSORT is a reporting guideline, not a design guideline: it does not tell you how to run a trial, only what to say about how it was run.

CONSORT sits alongside, and is cross-referenced with, the general statistical reporting guidance that applies to any quantitative study, such as the SAMPL guidelines for basic statistical reporting in biomedical journals (Lang & Altman, 2015). Where SAMPL tells you how to report an estimate, a confidence interval or a p-value correctly, CONSORT tells you which design features and which results a trial report must include in the first place; the two are complementary rather than overlapping.

Why it exists

Before CONSORT, trial reports varied so much in what they disclosed that readers often could not judge whether a result was reliable. A classic study found that trials with inadequate allocation concealment or no blinding produced systematically different, often inflated, estimates of treatment effect (Moher et al., 1998). If a report does not say how allocation was concealed or whether outcome assessors were blinded, a reader cannot tell whether the same bias is present.

CONSORT exists to close that gap by making these design features, and the flow of participants through the trial, a standard part of what every report discloses. This matters for two groups of readers in particular: systematic reviewers, who need complete information to judge risk of bias and pool results, and clinicians or policymakers, who act on a trial's stated effect size without being able to re-run the study themselves.

For a doctoral researcher, the practical value is narrower but just as real. An examiner reading your trial chapter is, in effect, doing the same job as a peer reviewer: checking whether what you claim follows from what you actually did. A chapter that answers the CONSORT items as it goes along gives the examiner less reason to raise a methodological query at the viva, because the information they would otherwise have to ask for is already on the page.

Which designs it fits

CONSORT 2025 is written for the two-arm, parallel-group, individually randomised trial, and this is the version most people mean when they say "CONSORT". Many trials, however, depart from that basic design, and the CONSORT group has published extensions that add or modify items for each one.

CONSORT 2025 and its main extensions by trial design
Trial designWhat changesExtension to use
Cluster randomisedRandomisation happens at the group level, not the individualCONSORT extension for cluster trials
Non-inferiority or equivalenceThe hypothesis and margin of interest differ from a superiority trialCONSORT extension for non-inferiority and equivalence trials
Pragmatic trialConducted under usual-care conditions to inform real-world decisionsCONSORT extension for pragmatic trials
Pilot or feasibility studyAim is feasibility, not estimating a treatment effectCONSORT extension for pilot and feasibility trials
More than two armsMore comparisons and allocation groups to describeCONSORT extension for multi-arm trials
Within-person or crossoverEach participant receives more than one treatment, in sequenceCONSORT extension for crossover trials

Before you draft your results section, check the EQUATOR Network library for an extension that matches your design; using the base checklist alone for a cluster or non-inferiority trial will miss items specific to that design.

Where CONSORT does not apply

CONSORT is specifically for randomised trials, and using it where randomisation did not occur misapplies the checklist. A cohort, case-control or cross-sectional study should be reported against STROBE instead (von Elm et al., 2007), because the items that matter most in an observational design, such as how confounders were measured and adjusted for, are not part of CONSORT at all.

CONSORT also does not cover the trial protocol itself. A protocol, written and registered before recruitment begins, is reported against SPIRIT 2025, a related but separate statement covering what a trial plans to do rather than what it did (Chan et al., 2025). Diagnostic accuracy studies, animal experiments and case reports each have their own guideline (STARD, ARRIVE and CARE respectively); CONSORT should not be stretched to cover them.

Why compliance matters, and what the evidence shows

A Cochrane systematic review examined whether journals endorsing CONSORT, and the act of following it, were associated with more complete reporting of randomised trials, and found that CONSORT endorsement by a journal was associated with better reporting of several key items, such as allocation concealment and sample size calculation, compared with trials in non-endorsing journals (Turner et al., 2012). The review also noted that reporting remained incomplete even in endorsing journals, so adopting CONSORT is associated with improvement, not a guarantee of complete reporting.

How it is applied in practice

Most major medical journals require authors submitting a randomised trial report to supply a completed CONSORT checklist alongside the manuscript, stating the page or paragraph where each item is addressed, and many make this a condition of peer review rather than a optional courtesy. The International Committee of Medical Journal Editors expects trials submitted to member journals to have been registered in a public registry before enrolment, which supports the same aim as CONSORT: letting readers check what was planned against what was reported.

In practice, researchers use CONSORT twice: once while designing the trial and writing the protocol (alongside SPIRIT), so the information CONSORT will later ask for is actually collected, and again while drafting the results, working through the checklist item by item rather than treating it as a final tick-box exercise. The flow diagram is usually drawn from trial management records, not reconstructed from memory at the writing stage.

A doctoral trial usually has a small team and a single site, so some CONSORT items, such as multicentre coordination, will genuinely not apply; state this plainly rather than leaving the item unaddressed. Where a supervisor or statistician was responsible for generating the randomisation sequence or for analysis while blinded to allocation, say so by name or role, since who did what is itself part of what CONSORT asks a report to disclose.

An illustrative example

The passage below is a hypothetical illustration, not a quotation from a published trial.

Illustrative before-and-after reporting against CONSORT 2025 (hypothetical trial)
ElementWithout CONSORTWith CONSORT
Randomisation"Patients were randomised to treatment or control.""Participants were assigned using a computer-generated random sequence in blocks of four, stratified by site, with allocation concealed using sequentially numbered sealed envelopes held by an independent coordinator."
Blinding"The study was double-blind.""Participants, outcome assessors and the statistician were blinded to allocation; identical placebo tablets were used, and blinding was checked by asking assessors to guess allocation at trial end (correct in 51% of guesses)."
Participant flowNo diagram; attrition mentioned only in the discussionA CONSORT flow diagram showing numbers screened, randomised, receiving the allocated intervention, lost to follow-up (with reasons) and analysed in each arm
Primary outcome"The treatment group improved more (p = 0.03).""Mean change in score was 4.2 points greater in the treatment arm (95% CI 0.4 to 8.0; p = 0.03), the pre-specified primary outcome analysed by intention to treat."
Changes to the trialNot mentioned"The planned sample size was increased from 120 to 160 after a blinded interim review of recruitment rate, before any outcome data were examined; this change is registered in the protocol amendment."

The second column in each row answers a question a careful reviewer would otherwise have to ask, and each answer maps onto a specific CONSORT checklist item rather than being added for its own sake.

What to check before you submit

  • Have you stated the trial design in the title or abstract, including the word "randomised"?
  • Does the methods section give the method of sequence generation, the type of allocation concealment, and who was blinded?
  • Is there a CONSORT flow diagram showing every group, with numbers at each stage and reasons for exclusion or loss to follow-up?
  • Is the primary outcome, and how it was analysed, stated exactly as it was pre-specified in the registered protocol?
  • Are harms and adverse events reported for every arm, not only the intervention arm?
  • If your trial is cluster, non-inferiority, pragmatic, pilot, multi-arm or crossover, have you also used the matching CONSORT extension?
  • Official checklist and source: CONSORT and SPIRIT (consort-spirit.org) .

Key takeaways

  • CONSORT 2025 is a 30-item checklist and flow diagram for reporting randomised trials, maintained by an international methodology group (Hopewell et al., 2025).
  • It exists because incomplete reporting of randomisation and blinding is linked to biased effect estimates (Moher et al., 1998).
  • It fits parallel-group trials directly, and cluster, non-inferiority, pragmatic, pilot and crossover trials through its extensions.
  • It does not apply to observational studies (use STROBE (von Elm et al., 2007)), protocols (use SPIRIT (Chan et al., 2025)) or non-trial designs.
  • Journal endorsement of CONSORT is associated with more complete reporting, though not with perfect reporting (Turner et al., 2012).
  • CONSORT complements, rather than replaces, general statistical reporting guidance such as SAMPL (Lang & Altman, 2015).
Your next step

Want to apply this to your own study?

  1. 1Tell us your topic, data and deadline
  2. 2A subject mentor reviews your work with you
  3. 3You get a plan and a quote
Manuscript statistics

References

  1. Chan, A.-W., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., . . . Hróbjartsson, A. (2025). SPIRIT 2025 statement: Updated guideline for protocols of randomised trials. BMJ, 389, e081477. https://doi.org/10.1136/bmj-2024-081477
  2. Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., Bhandari, N., Butcher, N. J., Campbell, M. K., Chidebe, R. C. W., Elbourne, D., Farmer, A., Fergusson, D. A., Golub, R. M., Goodman, S. N., . . . Boutron, I. (2025). CONSORT 2025 statement: Updated guideline for reporting randomised trials. BMJ, 389, e081123. https://doi.org/10.1136/bmj-2024-081123
  3. Lang, T. A., & Altman, D. G. (2015). Basic statistical reporting for articles published in biomedical journals: The "Statistical Analyses and Methods in the Published Literature" or the SAMPL guidelines. International Journal of Nursing Studies, 52(1), 5–9. https://doi.org/10.1016/j.ijnurstu.2014.09.006
  4. Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998). Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? The Lancet, 352(9128), 609–613.
  5. Turner, L., Shamseer, L., Altman, D. G., Schulz, K. F., & Moher, D. (2012). Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane systematic review and meta-analysis. Systematic Reviews, 1, 60. https://doi.org/10.1186/2046-4053-1-60
  6. von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. The Lancet, 370(9596), 1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X

How to cite this article

Choose your referencing style, then copy. Check your university's or journal's guide for local variations.

PhD Research Lab Academy. (2026, October 8). CONSORT 2025: what it is, when to use it and how to report a randomised trial. PhD Research Lab. https://www.phdassistance.com/academy/guidelines/consort/

PhD Research Lab Academy. “CONSORT 2025: What It Is, When to Use It and How to Report a Randomised Trial.” PhD Research Lab, 8 Oct. 2026, www.phdassistance.com/academy/guidelines/consort. Accessed [access date].

PhD Research Lab Academy (2026) CONSORT 2025: what it is, when to use it and how to report a randomised trial. PhD Research Lab. Available at: https://www.phdassistance.com/academy/guidelines/consort/ (Accessed: [access date]).

PhD Research Lab Academy. “CONSORT 2025: What It Is, When to Use It and How to Report a Randomised Trial.” PhD Research Lab. October 8, 2026. https://www.phdassistance.com/academy/guidelines/consort.

PhD Research Lab Academy, ‘CONSORT 2025: What It Is, When to Use It and How to Report a Randomised Trial’ (PhD Research Lab, 8 October 2026) <https://www.phdassistance.com/academy/guidelines/consort> accessed [access date].

PhD Research Lab Academy. CONSORT 2025: what it is, when to use it and how to report a randomised trial [Internet]. PhD Research Lab; 2026 Oct 8 [cited [access date]]. Available from: https://www.phdassistance.com/academy/guidelines/consort/

PhD Research Lab Academy, “CONSORT 2025: what it is, when to use it and how to report a randomised trial,” PhD Research Lab, Oct. 8, 2026. [Online]. Available: https://www.phdassistance.com/academy/guidelines/consort. [Accessed: [access date]].

@online{guideline_consort_2026,
  author = {{PhD Research Lab Academy}},
  title = {{CONSORT 2025: what it is, when to use it and how to report a randomised trial}},
  organization = {PhD Research Lab},
  date = {2026-10-08},
  url = {https://www.phdassistance.com/academy/guidelines/consort},
  urldate = {[access date]}
}

This article is for learning. Use it to understand the method and cite the original sources above in your own work; do not copy or submit it as your own.

CONSORT 2025Need help applying it to your study?
Manuscript statistics